Viral Drugs (list) Flashcards
ABACAVIR Group Sub-Group MOA Other/Resistance Viruses Treated Side Effects
Group:
Antiretroviral
Sub-Group:
Nucleoside Reverse Transciptase inhibitor (NRTI)
MOA:
- Converted to Triphosphate Nucleotide by HOST cell Kinases
- Terminate Viral DNA chain SYNTHESIS by REVERSE TRANSCRIPTASE
Viruses Treated:
HIV
Side Effects:
- Mitochondrial Polymerase could also be targeted
ACYCLOVIR Group Sub-Group MOA Other/Resistance Viruses Treated Side Effects
Group:
Anti-Viral
MOA:
-Targets Nucleic Acid Synthesis by the herpesevirus by a nuclceoside analogue that MUST be METABOLLICALLY activated
- Acts as a competitive inhibitor of dGTP
- Gets incorporated into growing chain
- Traps the polymerase on the ACV-terminated DNA chain when the next dNTP binds
Viruses Treated: Herpes simplex (I and II), Varicella Zoster, Cytomegalovirus
AMANTADINE Group Sub-Group MOA Other/Resistance Viruses Treated Side Effects
Group:
Anti-Viral
MOA:
BLOCKS M2 CHANNEL NEEDED for H+ to enter the capsule of the virus so that RNP can be ejected into the host cell
Viruses Treated:
Influenza
Amprenavir Group Sub-Group MOA Other/Resistance Viruses Treated Side Effects
Group:
Antiretroviral
Sub-Group:
HIV-1 Protease Inhibitor
MOA:
- Work to inhibit active site of Aspartyl Protease of HIV
- Aspartyl Protease resposible for: gag, pol, Reverse Transcriptase, integrase, etc.
Other/Resistance:
- Resistance initially occurs at the enzyme’s active site then may spread to secondary locations
Viruses Treated:
HIV
ATAZNAVIR Group Sub-Group MOA Other/Resistance Viruses Treated Side Effects
Group:
Antiretroviral
Sub-Group:
HIV-1 Protease Inhibitor
MOA:
- Work to inhibit active site of Aspartyl Protease of HIV
- Aspartyl Protease resposible for: gag, pol, Reverse Transcriptase, integrase, etc.
Other/Resistance:
- Resistance initially occurs at the enzyme’s active site then may spread to secondary locations
- NO CYP34A inhibition
Viruses Treated:
HIV
BOCEPREVIR Group Sub-Group MOA Other/Resistance Viruses Treated Side Effects
Group:
Anti-Viral
MOA:
Inhibits NS3/4A protease that cleaves polypeptide of HCV into non-structural HCV proteins
Other/Resistance:
- HCV quickly mutates so resistance can rapidly be conferred
Viruses Treated:
HCV I
Didanosine (ddl) Group Sub-Group MOA Other/Resistance Viruses Treated Side Effects
Group:
Antiretroviral
Sub-Group:
Nucleoside Reverse Transciptase inhibitor (NRTI)
MOA:
- Converted to Triphosphate Nucleotide by HOST cell Kinases
- Terminate Viral DNA chain SYNTHESIS by REVERSE TRANSCRIPTASE
Viruses Treated:
HIV
Side Effects:
- Mitochondrial Polymerase could also be targeted
EFAVIRENZ Group Sub-Group MOA Other/Resistance Viruses Treated Side Effects
Group:
Antiretroviral
Sub-Group:
Non-competitive Nucleotide Inhibitor of HIV-1
MOA:
Allosteric Inhibitor that binds to the p66 binding pocket of HIV-1 reverse transciptase
Other/Resistance:
Does not penetrated CNS like Nevirapine
Viruses Treated:
HIV
EMITRICITABINE Group Sub-Group MOA Other/Resistance Viruses Treated Side Effects
Group:
Antiretroviral
Sub-Group:
Nucleoside Reverse Transciptase inhibitor (NRTI)
MOA:
- Converted to Triphosphate Nucleotide by HOST cell Kinases
- Terminate Viral DNA chain SYNTHESIS by REVERSE TRANSCRIPTASE
Viruses Treated:
HIV
Side Effects:
- Mitochondrial Polymerase could also be targeted
ENFUVIRTIDE Group Sub-Group MOA Other/Resistance Viruses Treated Side Effects
Group:
Antiretroviral
Sub-Group:
Fusion Inhibitors
MOA:
T-20, It’s a Synthetic Peptide drug that mimics HR2, binds to HR1 and prevents HR2-HR1 interaction
Viruses Treated:
HIV
FOSCARNET Group Sub-Group MOA Other/Resistance Viruses Treated Side Effects
Group:
Anti-viral
Sub-Group:
Nucleic Acid Synthesis inhibitor
MOA:
Inhibits DNA polymerase noncompetively by binding PPi and preventing PPi bond cleavage
Chain termination results
GANCICLOVIR Group Sub-Group MOA Other/Resistance Viruses Treated Side Effects
Group:
Anti-Viral
MOA:
-Targets Nucleic Acid Synthesis by the herpesevirus by a nuclceoside analogue that MUST be METABOLLICALLY activated
- Acts as a competitive inhibitor of dGTP
- Gets incorporated into growing chain
- Traps the polymerase on the ACV-terminated DNA chain when the next dNTP binds
Viruses Treated: Herpes simplex (I and II), Varicella Zoster, Cytomegalovirus
Indinavir Group Sub-Group MOA Other/Resistance Viruses Treated Side Effects
Group:
Antiretroviral
Sub-Group:
HIV-1 Protease Inhibitor
MOA:
- Work to inhibit active site of Aspartyl Protease of HIV
- Aspartyl Protease resposible for: gag, pol, Reverse Transcriptase, integrase, etc.
Other/Resistance:
- Resistance initially occurs at the enzyme’s active site then may spread to secondary locations
Viruses Treated:
HIV
LAMIVUDINE (3-TC) Group Sub-Group MOA Other/Resistance Viruses Treated Side Effects
Group:
Antiretroviral
Sub-Group:
Nucleoside Reverse Transciptase inhibitor (NRTI)
MOA:
- Converted to Triphosphate Nucleotide by HOST cell Kinases
- Terminate Viral DNA chain SYNTHESIS by REVERSE TRANSCRIPTASE
Viruses Treated:
HIV, HBV
Side Effects:
- Mitochondrial Polymerase could also be targeted
Lopinavir Group Sub-Group MOA Other/Resistance Viruses Treated Side Effects
Group:
Antiretroviral
Sub-Group:
HIV-1 Protease Inhibitor
MOA:
- Work to inhibit active site of Aspartyl Protease of HIV
- Aspartyl Protease resposible for: gag, pol, Reverse Transcriptase, integrase, etc.
Other/Resistance:
- Resistance initially occurs at the enzyme’s active site then may spread to secondary locations
Viruses Treated:
HIV